All In Biotech

Drug Trial Radar · NCT07416526

A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

A Multicenter, Randomized, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of NXT007 Prophylaxis Versus Factor VIII Prophylaxis in People With Hemophilia A Without Inhibitors

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 138 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

138

Planned (sponsor's estimate)

Start

May 15, 2026

Primary completion

Sep 23, 2027

Study completion Sep 23, 2031

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Chugai Pharmaceutical
First posted
Feb 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of NXT007 prophylaxis compared with Factor VIII (FVIII) prophylaxis in participants with severe or moderate congenital hemophilia A without FVIII inhibitors. The study will include people aged ≥12 years old who have been on FVIII prophylaxis treatment prior to study entry.

Conditions

  • Hemophilia A

Interventions

  • NXT007Combination product

    NXT007 will be administered subcutaneously (SC) using an integrated drug-device combination product.

  • Human Coagulation Factor VIIIDrug

    Factor VIII (FVIII) prophylaxis standard of care (SOC) will be administered at the dose and frequency as stated in the local labels and per local country practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Bleed Rate (ABR) for Treated Bleeds Over the Main Study Treatment PeriodTime frame: 6 months

Locations

36 sites in 18 countries. Site status is shown where the registry gives one.

  • University of Colorado Hemophilia and Thrombosis Center

    Aurora, Colorado · Recruiting

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa · Recruiting

  • Arbesu Hematologia

    Godoy Cruz, Mendoza Province, Argentina · Recruiting

  • Instituto de Hematología Y Medicina Clínica Dr. Rubén Dávoli

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Universitätsklinikum AKH Wien

    Vienna, Austria · Recruiting

  • Hemocentro Da UNICAMP

    Campinas, São Paulo, Brazil · Recruiting

  • Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP - PPDS

    Ribeirão Preto, São Paulo, Brazil · Recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Rigshospitalet-Blegdamsvej 9

    Copenhaen, Denmark · Recruiting

  • Groupement Hospitalier Est-Hopital Femme Mere enfant/Hospice civils de lyon

    Bron, France · Recruiting

  • CHU de Lille - Institut Cœur Poumon

    Lille, France · Recruiting

  • AP-HP - Hôpital Bicêtre

    Le Kremlin-Bicêtre, Val-de-Marne, France · Recruiting

  • Universitätsklinikum Bonn

    Bonn, North Rhine-Westphalia, Germany · Recruiting

  • Eszak-Pesti Centrumkorhaz -Honvedkorhaz

    Budapest, Pest County, Hungary · Recruiting

  • Azienda Ospedaliera Universitaria Federico II

    Naples, Campania, Italy · Recruiting

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    Milan, Lombardy, Italy · Recruiting

  • IRCCS Istituto Clinico Humanitas

    Rozzano, Lombardy, Italy · Recruiting

  • Azienda Ospedaliera Universitaria Careggi

    Florence, Tuscany, Italy · Recruiting

  • Nara Medical University Hospital

    Kashihara-shi, Nara, Japan · Recruiting

  • Tokyo Medical University Hospital

    Shinjuku-Ku, Tokyo, Japan · Recruiting

  • Universitair Medisch Centrum Utrecht

    Utrecht, Netherlands · Recruiting

  • Haemophilia Comprehensive Care Centre

    Parktown, Gauteng, South Africa · Recruiting

  • Chonnam National University Hwasun Hospital

    Hwasun-gun, South Korea · Recruiting

  • Kyung Hee University Hospital at Gangdong

    Gangdong-gu, Seoul, South Korea · Recruiting

  • Hospital Universitario Vall d'Hebron - PPDS

    Barcelona, Spain · Recruiting

  • Hospital Universitario La Paz - PPDS

    Madrid, Spain · Recruiting

  • Hospital Regional Universitario de Malaga ? Hospital General

    Málaga, Spain · Recruiting

  • Hospital Universitario Virgen del Rocio - PPDS

    Seville, Spain · Recruiting

  • Hospital Universitari i Politecnic La Fe de Valencia

    Valencia, Spain · Recruiting

  • Universitätsspital Zürich

    Zurich, Switzerland · Recruiting

  • Taichung Veterans General Hospital

    Taichung, Taiwan · Recruiting

  • Tri-Service General Hospital

    Taipei, Taiwan · Recruiting

  • University Hospital of Wales

    Cardiff, United Kingdom · Recruiting

  • St Thomas' Hospital

    London, United Kingdom · Recruiting

  • Churchill Hospital

    Oxford, United Kingdom · Recruiting

  • The Royal London Hospital

    London, Middlesex, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.